Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 1,727.7% in August

by · The Cerbat Gem

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,196 shares, an increase of 1,727.7% from the August 15th total of 1,871 shares. Based on an average daily volume of 46,883 shares, the short-interest ratio is presently 0.7 days. Approximately 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Several research firms have weighed in on NVZMY. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Check Out Our Latest Research Report on NVZMY

Novozymes A/S Trading Down 2.2%

Shares of OTCMKTS NVZMY traded down $1.46 during midday trading on Thursday, reaching $65.89. 18,855 shares of the stock were exchanged, compared to its average volume of 66,569. The business has a 50-day simple moving average of $66.29 and a two-hundred day simple moving average of $61.45. The company has a market capitalization of $27.31 billion, a price-to-earnings ratio of 41.70, a P/E/G ratio of 2.98 and a beta of 0.93. Novozymes A/S has a 12 month low of $49.90 and a 12 month high of $75.27. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last released its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). The firm had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.27 billion. Novozymes A/S had a net margin of 14.70% and a return on equity of 6.60%. As a group, equities research analysts expect that Novozymes A/S will post 2.47 EPS for the current year.

Institutional Investors Weigh In On Novozymes A/S

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B increased its holdings in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.

See Also